

# Battelle

*The Business of Innovation*

**Centers for Public Health  
Research and Evaluation**

100 Capitola Drive, Suite 301  
Durham, North Carolina 27713-4411  
(919) 544-3717 Fax (919) 544-0830

October 29, 2005


Diane R. Burkom, MA  
Battelle CPHRE  
6115 Falls Road, Suite 200  
Baltimore, MD 21209

Dear Ms. Burkom:

As acting chair of the Battelle/CPHRE Institutional Review Board (IRB) I have reviewed the continuing review and modifications submission dated 10/24/2005 for the study entitled "Second Injury Control and Risk Survey (ICARIS-2)" (FG446622-02) and grant expedited approval to continue with this study. The modifications are minor and do not change the risk/benefits ratio.

As with all Battelle/CPHRE studies, this study will be subject to continuing review again next year. We will send you notification at the appropriate time. In the meantime, should any additional changes occur in your protocol or questionnaire, please inform the IRB and submit the changes for review. Similarly, the IRB needs to be notified in the event of any injury or unexpected outcome arising from this study.

Sincerely,



Christopher W. Lyu, MPA  
Acting IRB Chair

cc: Brigette Brevard  
Kevin Heaton  
Jan Jaeger

**Battelle/Centers for Public Health Research and Evaluation**

100 Capitola Drive, Suite 301

Durham, NC 27713

Federal-wide Assurance No. FWA00004696

**INSTITUTIONAL REVIEW BOARD NOTICE OF APPROVAL**

PROJECT DIRECTOR: Diane R. Burkom

PROJECT TITLE: Second Injury Control and Risk Survey (ICARIS-2)

CLIENT: CDC

PROTOCOL DATE: 10/24/05

BATTELLE PROJECT CODE: FG446622-02

or PROPOSAL NUMBER:      (if preaward)

NATURE OF REVIEW: (check one)

|                                     |
|-------------------------------------|
| <input type="checkbox"/>            |
| <input checked="" type="checkbox"/> |
| <input type="checkbox"/>            |

FULL MEETING DATE: \_\_\_\_\_

EXPEDITED (specify reason): minimal risk; minor change; no change to risk/benefits

EXEMPT (specify reason): \_\_\_\_\_

TYPE OF APPROVAL: (check one)

|                                     |
|-------------------------------------|
| <input type="checkbox"/>            |
| <input type="checkbox"/>            |
| <input type="checkbox"/>            |
| <input checked="" type="checkbox"/> |
| <input checked="" type="checkbox"/> |

PRELIMINARY. SCHEDULE NEXT REVIEW PRIOR TO INVOLVEMENT OF HUMAN SUBJECTS.

PRETEST/PILOT TEST. SCHEDULE NEXT REVIEW PRIOR TO FULL IMPLEMENTATION.

FULL IMPLEMENTATION.

RENEWAL.


AMENDMENT DATED 10/24/2005

**Please note the following requirements:**

**PROBLEMS OR ADVERSE REACTIONS:** If any problems in treatment of human subjects or unexpected adverse reactions occur as a result of this study, you must notify the IRB Chairperson immediately, then complete an Adverse Event/Incident Report and forward it to the CPHRE IRB Administrator.

**CHANGES IN PROTOCOL:** If there are any changes in procedures or study protocol, you must notify the IRB Chairperson and submit the revisions for review before they are implemented.

**RENEWAL:** You are required to apply for renewal of approval at least annually for as long as the study is active. Your next continuing review date should be on or before 10/29/06.

  
IRB Chairperson

10/29/05  
Date

Christopher W. Lyu, MPA  
Print or Type Name

Copy of approved Informed Consent on file.

cc: Project Director  
IRB Administrator